Bavarian Nordic A/S - ADR does not currently pay a dividend. The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives ... to arise getting ...
"Since the outbreak of mpox last year, Bavarian Nordic has supplied millions of doses of our vaccine to more than 70 countries worldwide ... vaccines were scarce while demand was high. Federal ...
But clinics in San Francisco, New York and other major cities say they still don't have enough shots to meet demand ... Bavarian Nordic facility were awaiting the U.S. certification announced ...
In short: The demand for the Shingrix vaccine is high across Australia, with more than 1.1 million doses administered since November. Some in the ACT have reported waiting months for their shots ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Bavarian Nordic's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents. A recently granted patent (Publication Number: US11918639B2 ...
Vaccines Market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results